 This finding opened the door to a broader understanding of the role of prostaglandins in the body.Vane and a team from the Wellcome Foundation had identified a lipid mediator they called “PG-X,” which inhibited platelet aggregation.PG-X, which later would become known as prostacyclin, was 30 times more potent than any other known anti-aggregatory agent.